Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Thrombosis Research

• Publication date

  1988-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0049-3848(88)90071-0PMID 3144052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effect of Human Recombinant Tissue-Type Plasminogen Activator on Clinical and Laboratory Parameters of Hemostasis and Systemic Plasminogen Activation in the Dog and the Rat

  1988cited by this paper
• 258 Role of human U937 monocytes in controlling single-chain urokinase-initated plasminogen activation

  1988cited by this paper
• Simple canine model of arterial thrombosis with endothelial injury suitable for investigation of thrombolytic agents.

  1988cited by this paper
• Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation.

  1988cited by this paper
• Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: The European experience

  1987cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.

  1987cited by this paper
• The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.

  1987cited by this paper
• Thrombolysis with Recombinant Human Single-Chain Urokinase-Type Plasminogen Activator (rscu-PA): Dose–Response in Dogs with Coronary Artery Thrombosis

  1987cited by this paper
• Tissue-type plasminogen activator.

  1987cited by this paper
• Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.

  1987cited by this paper
• Tissue Plasminogen Activator: An Evaluation of Clinical Efficacy in Acute Myocardial Infarction

  1987cited by this paper
• Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial.

  1987cited by this paper
• Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction.

  1987cited by this paper
• Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.

  1987cited by this paper
• Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy.

  1987cited by this paper
• Clinical pharmacology of coronary thrombolysis.

  1987cited by this paper
• Pharmacology of thrombolytic drugs.

  1986cited by this paper
• Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.

  1986cited by this paper
• D-Phe-Pro-Arg-Chloromethylketone: Its Potential Use in Inhibiting the Formation of In Vitro Artifacts in Blood Collected During Tissue-Type Plasminogen Activator Thrombolytic Therapy

  1986cited by this paper
• Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.

  1986cited by this paper
• Human tissue-type plasminogen activator: from the laboratory to the bedside.

  1985cited by this paper
• The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits.

  1985cited by this paper
• Statistics in practice. Comparing the means of several groups.

  1985cited by this paper
• Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.

  1984cited by this paper
• Isolation and characterization of urokinase from human plasma.

  1982cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin.

  1979cited by this paper
• Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251

  1978cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION.

  1965cited by this paper
• Urokinase an activator of plasminogen from human urine. I. Isolation and properties.

  1957cited by this paper

• 2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics

  2022cites this paper
• Use of tissue plasminogen activator to alleviate postoperative subcutaneous ureteral bypass obstruction secondary to blood clot in seven cats

  2021cites this paper
• Systemic thrombolysis for acute ischemic stroke treatment

  2013cites this paper
• Sistemska tromboliza u liječenju akutnog ishemijskog moždanog udara

  2013cites this paper
• Study On The Comparative Efficacy Of Diagnostic Tests In The Early Diagnosis Of Canine Liver Diseases

  2012cites this paper
• The use of thrombolytic agents.

  2007cites this paper
• Table 1 . Properties of Thrombolytic Agents That Have Been Used in Cats and Dogs Thrombolytic Fibrin Agent Description Specificity Source IV Dosages Indications rtPA

  2007cites this paper
• Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator

  2006cites this paper
• Canine Model of Coronary Artery Thrombosis

  2005cites this paper
• Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase)

  2001cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• Thrombolytic Therapy in Dogs and Cats

  2001cites this paper
• Rationale for the bolus administration of fibrin-specific thrombolytic agents

  1997cites this paper
• Complicated Simplification of Dosage Regimen for Plasminogen Activators a

  1996cites this paper
• Thrombolytic properties of pro-urokinase mutants with mutation in the epidermal growth factor-like domain

  1995cites this paper
• Experimental combined thrombolytic therapy: The current position and directions of progress (review)

  1994cites this paper
• Pro‐urokinase and prekallikrein are both associated with platelets

  1993cites this paper
• Role of the glycosaminoglycan component of thrombomodulin in its acceleration of the inactivation of single-chain urokinase-type plasminogen activator by thrombin.

  1993cites this paper
• Thrombolytic properties of Desmodus (Vampire Bat) salivary plasminogen activator DSPAα1, alteplase and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis

  1993cites this paper
• Approach to the patient with venous thromboembolism. Treatment with thrombolytic agents.

  1992cites this paper
• Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.

  1992cites this paper
• Prevention of microvascular thrombosis with low-dose tissue plasminogen activator.

  1992cites this paper
• Effectiveness and safety of a single intravenous Bolus injection of tissue-type plasminogen activator in acute myocardial infarction

  1992cites this paper
• Bolus thrombolysis in venous thromboembolism.

  1992cites this paper
• Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age

  1992cites this paper
• Advances in thrombolytic therapy

  1992cites this paper
• Thrombolytic effect of tissue plasminogen activator in a cerebral embolic model.

  1991cites this paper
• Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction.

  1991cites this paper
• Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator.

  1991cites this paper
• Urokinase-mediated thrombolysis: a dose-response relationship in cats. Work in progress.

  1991cites this paper
• Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.

  1991cites this paper
• Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin.

  1991cites this paper
• Thrombolysis with Bolus Injections and Infusions of Tissue-type Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis

  1991cites this paper
• Fibrinolytic Properties of Single Chain Urokinase-type Plasminogen Activator (Pro-urokinase)

  1990cites this paper
• Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.

  1990cites this paper
• A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.

  1990cites this paper
• Rationale for bolus t-PA therapy to improve efficacy and safety.

  1990cites this paper
• The Protective Effect of Heparin in a Dog Model of Rethrombosis Following Pharmacologic Thrombolysis

  1990cites this paper
• Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.

  1990cites this paper